Increased risk for hepatocellular carcinoma in NAT2-slow acetylators and CYP2D6-rapid metabolizers

  1. Agúndez, J.A.G.
  2. Olivera, M.
  3. Ladero, J.M.
  4. Rodriguez-Lescure, A.
  5. Ledesma, M.C.
  6. Diaz-Rubio, M.
  7. Meyer, U.A.
  8. Benítez, J.
Revue:
Pharmacogenetics

ISSN: 0960-314X

Année de publication: 1996

Volumen: 6

Número: 6

Pages: 501-512

Type: Article

DOI: 10.1097/00008571-199612000-00003 GOOGLE SCHOLAR

Objectifs de Développement Durable